Two large drug makers are squaring off against the Netherlands as drug pricing increasingly becomes a flashpoint for governments looking to pay less for medicines.

In one instance, Vertex Pharmaceuticals (VRTX) has reportedly filed a lawsuit against the Ministry for Medical Care over the methods used to calculate the official maximum price for Orkambi, a cystic fibrosis treatment that is also at the center of a closely watched row over reimbursement in the U.K.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy